News | Mammography | January 12, 2021

This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately

This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately

January 12, 2021 — Therapixel announced that MammoScreen has successfully obtained the CE mark. After having received FDA clearance for commercial sales in the United States in March 2020, this artificial intelligence (AI) solution is now available in the European market.

MammoScreen automatically analyzes screening mammograms and indicates suspicious mammograms and lesions to the radiologist. According to the probability of malignancy and the degree of confidence of the algorithm, the software assigns a unique "MammoScreen Score" ranging from 1 to 10.

A clinical study conducted in 2019 and published in Radiology: AI, showed that radiologists assisted by MammoScreen have a better performance than without the software.

MammoScreen helps to increase the interpretation speed of benign images, giving readers more time to focus on cases requiring more attention.

Already installed in 14 hospitals and radiology practices in France for clinical evaluations, MammoScreen has generated a lot of enthusiasm among radiologists. Physicians perceive it as an intuitive and easy-to-use tool that helps reassure themselves in the interpretation and avoid missing cancers.

Breast cancer is one of the most common and deadliest cancers in women worldwide, affecting 1 in 8 women in their lifetime. The earlier this disease is diagnosed, the more effective the treatment is.

"We are proud to have received the CE Mark. This brings us a step closer to our goal of reducing breast cancer burden worldwide by improving breast cancer screening," said Pierre Fillard, Therapixel's Founder and Chief Scientific Officer.

"I am confident that MammoScreen will not only increase radiologists' performance but will also improve the patient experience by reassuring women faster," stated Matthieu Leclerc-Chalvet, CEO of Therapixel.

For more information: www.mammoscreen.com

Related Content

News | Radiology Education

August 9, 2022 — SBI is pleased to invite all members and nonmembers to submit original abstracts for presentation at ...

Time August 11, 2022
arrow
News | Ultrasound Women's Health

August 10, 2022 — TransMed7, LLC announced that the first clinical cases of the final commercial production version of ...

Time August 10, 2022
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is what you and your colleagues found to be most interesting in the field of medical imaging during the month of ...

Time August 01, 2022
arrow
News | RSNA

July 29, 2022 — The Radiological Society of North America (RSNA), in collaboration with the American Society of ...

Time July 29, 2022
arrow
News | Breast Imaging

July 28, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), for patients with multiple architectural ...

Time July 28, 2022
arrow
News | Mammography

July 28, 2022 — The National Comprehensive Cancer Network (NCCN) has published new NCCN Guidelines for Patients: Breast ...

Time July 28, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

July 27, 2022 — Viz.ai, a leading AI-powered disease detection and intelligent care coordination platform, announced it ...

Time July 27, 2022
arrow
News | Artificial Intelligence

July 26, 2022 — Aidoc, a leading provider of AI healthcare solutions, today announced a partnership with UofL Health, a ...

Time July 26, 2022
arrow
News | Breast Imaging

July 26, 2022 — Seno Medical’s Imagio Breast Imaging System, a revolutionary new modality in breast imaging, has ...

Time July 26, 2022
arrow
News | Oncology Information Management Systems (OIMS)

July 26, 2022 — The oncology information system market is expected to expand at a 7.8% CAGR. The oncology information ...

Time July 26, 2022
arrow
Subscribe Now